BofA initiated coverage of Oculis with a Buy rating and $22 price target. The company is clinical stage and focused on developing topical treatments for ocular disorders, the analyst tells investors in a research note. The firm is most bullish on OCS-01 as a therapeutic for diabetic macular edema and says the Oculis has several late stage assets with near-term clinical catalysts.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OCS:
- Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
- Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
- Oculis to Participate in Jefferies Healthcare Conference
- Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares
- Oculis Announces Launch of Proposed Public Offering of Ordinary Shares
